Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It has been shown to activate the immune system to generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced both local and systemic innate and adaptive immune activation, which has been associated with clinical benefit. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase II trial, with a phase Ib safety lead-in cohort. Another trial, in advanced melanoma, is expected to produce important proof of concept data for checkpoint inhibitor refractory patients within the next 6-12 months.
Targovax is also developing a neo-antigen cancer vaccine targeting tumors that express mutated forms of RAS – mutations known to drive cancer. The TG vaccine program has shown a signal of efficacy in a 32- patient trial with TG01 in resected pancreatic cancer. A next generation product candidate, TG02 is currently tested as monotherapy and will also be tested in combination with Keytruda® (an anti-PD1 Check point inhibitor, CPI).
Primary therapeutic area(s): Immunotherapy
Phase of development: Phase I/II
eTheRNA is a clinical stage developer of mRNA-based immunotherapies for cancer, focusing on therapies that activate the immune system by programming dentritic cells (DC) with synthetic mRNA. To date it has completed 4 clinical studies (Phase I and II) and has 3 studies underway. The company recently opened a new GMP facility which also provides contract manufacturing services. eTheRNA concluded a Series A financing in 2016 and is supported by a strong sector-specialised investor syndicate.
Primary therapeutic area(s): eTheRNA immunotherapies is a clinical stage developer of mRNA-based immunotherapies for cancer, focusing on therapies that prepare and activate the immune system by programming dentritic cells (DC) with synthetic mRNA. It also has an interest in infectious disease therapies.
Phase of development: Clinical Development – phase I/II.
Astrocyte is a small asset-centric CNS drug development company based in Cambridge, MA, USA. The company has raised $4.7M in private financing and been awarded $4M in NIH grants.
Primary therapeutic area(s): Acute neurology including acute ischemic stroke (AIS), traumatic brain injury (TBI) and concussion, which are leading causes of death and disability worldwide.
Phase of development: Preclinical. Efficacy demonstrated in porcine and rodent AIS/TBI models; exploratory toxicology studies completed; GMP manufacturing campaign in progress; US IND in Q4 2018. AST-004 is a novel small molecule A3R agonist that activates mitochondrial energy production in astrocytes and promotes multiple intrinsic neuroprotective mechanisms.
MVI is developing “off-the-shelf”, stable and safe T-cell activating therapies that synergize with checkpoint inhibitors and androgen receptor antagonists. MVI vaccines have exceptionally low COG and are administered by simple intradermal injection at microgram doses – resulting in ideal combinatorial agents to pair with checkpoint inhibitors and AR antagonists. MVI vaccines are clinically ready for combination trials, having demonstrated good safety, tolerability and early efficacy signals.
Collecting additional information.
HPBio is a specialty biotech company focused on innovative cutting-edge technologies for analysis of toxic metabolites, biomarker proteins, bacteria, tumor cells, rare metals (such as Neodymium, Lithium), based on our ‘AptaCut & AptaLink’ technology. HPbio has demonstrated excellent results when it comes to addressing the biomarker proteins on the surface of cells. HPbio’s aptamer product can bring microvesicle carriers (liposomes, exosomes, lisosomes and hybridosome) very specifically to the target cells. HPBio has also filed multiple patents on new aptamer technology such as Aptablotting assay that involves direct and indirect aptamer recognition. HPBio’s unique assay platform supports the screening and design of aptatope for high sensitive diagnostic use. We would like to arrange a meeting with you at JPM to update the progress of our technology, ‘AptaCut & AptaLink’, as well as internal pipeline for out-licensing discussion, including Obesity, Allergy, Wound/Scar free healing, Neurodegenerative disease programs.
Primary therapeutic area(s): Obesity, Wound/Scar treat, Allergy, Neurodegenerative disease
Phase of development: Preclinical
Elasmogen delivers next generation therapeutics called soloMERs that are small, robust, single-domain (multi-functional) and bind unique epitopes (increased potency).
Primary therapeutic area(s): Ophthalmology, oncology, inflammation, auto-immune diseases
Phase of development: Late pre-clinical
MGI Tech Co., Ltd. (MGI), is a member of the BGI Group of companies, one of the world’s largest genomics organizations. As the leading manufacturer and developer of BGI’s proprietary NGS instrumentation, the global MGI organization provides comprehensive products and services for fully-automated, real-time, whole picture and lifelong genetic analysis in life science research. With the mission to develop and commercialize advanced life science tools for future healthcare, we are devoted to bringing innovative equipment and solutions to our customers and advancing precision medicine, agriculture and healthcare around the world.
Primary therapeutic area(s): Cancer, prenatal, all health related diagnostics
Phase of development: Products on market
ProMIS is a development stage biotechnology company developing antibody therapeutics selectively targeting toxic oligomers, the root cause of neurodegenerative diseases; Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
Primary therapeutic area(s): Central nervous system diseases (CNS): Alzheimer’s disease, Parkinson’s disease, ALS
Phase of development: Preclinical development for Alzheimer’s, Parkinson’s and ALS
Atom Bioscience founded in 2012 in China and mainly focused on new drug discovery and development on metabolic diseases and anti-cancer. The management team members are mainly from the US and have extensive experiences on pharmaceutical industry.
Atom Bioscience has completed A and A+ Rounds of financing. Investors are KAITAI Capital, YouChoose Capital, Ch-gemstone Capital and etc.
Primary therapeutic area(s): ABP-671 from Atom Bioscience is under Phase 1 clinical trials in the US. ABP-671 is an inhibitor of renal urate transporter 1 (URAT1) whose function is to increase the excretion of uric acid by the kidneys. ABP-671 has demonstrated excellent efficacy at low dose in lowering serum uric acid levels and showed great pharmacokinetics (PK) in recent Phase 1 study. Its pre-clinical results showed that ABP-671 did not show any toxicity at 500 mg/kg of NOAEL both in rats and monkeys tox studies. ABP-671 may become the most potent and safe drug for the treatment of gout and hyperuricemia worldwide. Besides ABP-671, ABP-6016 showed remarkable potency for treatment of NASH with the maximum tolerated dose over 3 g/kg in mice. ABP-431, which greatly inhibited three types of cancers in nude mice, is under investigation for treatment of gastric cancer, colon cancer and breast cancer. Both compounds are under pre-clinical development, will enter into the clinical trials in 2020.
Phase of development:
- ABP-671 for gout treatment is in phase 1 clinical trials in the US.
- ABP-6016 for NASH treatment is under pre-clinical studies.
- ABP-431 for anti-cancer is under pre-clinical studies.
GLAdiator Biosciences is a therapeutic company formed in 2018 based upon broad cancer targeting platform with drug development experts from Bayer and supported by world class scientific advisory board.
Primary therapeutic area(s): Oncology
Phase of development: Pre-clinical
ALPS Global Holding Berhad